Background: In the era of carbapenem resistance, the use of effective beta lactam - beta lactamase inhibitor (BL - BLI) combination drugs could serve as a carbapenem sparing strategy in the appropriate clinical situation. We therefore attempted to study the in vitro susceptibilities of cefepime-tazobactam, a new BL - BLI combination drug.
No takes yet. Share an insight, caveat, or question.
Panchatcharam et al. (2012) studied this question.